Member Login
Market Reports
 |
|
EXECUTIVE SUMMARY 1. APHERESIS PRODUCTS MARKET 2. THE HEMOSTASIS PRODUCTS MARKET 3. THE STEM CELL THERAPY PRODUCTS MARKET 4.1 Aastrom Biosciences, Inc. LIST OF EXHIBITS Exhibit ES-1: Advantages and Disadvantages of Apheresis Platelets Exhibit ES-2: Apheresis Equipment and Disposables, Market Forecast, Exhibit ES-3: Blood Demand, by Condition/Procedure Exhibit ES-4: Hemostasis Products, Market Forecast, 2001-2007 Exhibit ES-5: Advantages and Disadvantages of Stem Cells, by Source Exhibit ES-6: Stem Cell Therapy Products, Market Forecast, 2001-2007 Exhibit ES-7: Apheresis, Hemostasis, and Stem Cell Therapy Products, Market Exhibit 1-1: Whole-Blood Platelets Versus Apheresis Platelets Exhibit 1-2: Advantages and Disadvantages of Apheresis Platelets Exhibit 1-3: Leukoreduced Blood Products, Cost Forecast, 2001-2007 Exhibit 1-4: 2001, Blood Product Reimbursement Rates Exhibit 1-5: Procedure Times for Manual and Apheresis Blood Collection Exhibit 1-6: Apheresis Donation Interval Guidelines Exhibit 1-7: Goals of Therapeutic Apheresis, by Type Exhibit 1-8: Therapeutic Apheresis Categories Exhibit 1-9: Guidelines for Therapeutic Apheresis, by Disease Exhibit 1-10: Apheresis Recommendations for Neurologic Conditions Exhibit 1-11: 2001, United States Patient Registrants for Kidney and Exhibit 1-12: 2001, Kidney and Kidney-Pancreas Transplantation Survival Exhibit 1-13: Therapeutic Apheresis Indications Covered by Medicare Exhibit 1-14: 2002, Apheresis Centrifugation Systems Exhibit 1-15: 2002, Hollow-Fiber Membrane Filtration Systems Exhibit 1-16: Therapeutic Apheresis Systems, by Technique Exhibit 1-17: Apheresis, Procedure Volumes Forecast, by Type, 2001-2007 Exhibit 1-18: Donor Apheresis, Procedure Volumes Forecast, 2001-2007 Exhibit 1-19: Therapeutic Apheresis, Procedure Volumes Forecast, 2001-2007 Exhibit 1-20: Apheresis Equipment and Disposables, Market Forecast, Exhibit 1-21: 2001, Apheresis Equipment and Disposables Market, Share Exhibit 2-1: Blood Demand, by Condition/Procedure Exhibit 2-2: Recommendations For Use of Immunoglobulin Intravenous, by Exhibit 2-3: Blood Collection, Procedure Volumes Forecast, 2001-2007 Exhibit 2-4: Blood Transfusion, Procedure Volumes Forecast, 2001-2007 Exhibit 2-5: 2002, Selected Blood Substitute Products Exhibit 2-6: Blood Substitute Products, Market Forecast, 2001-2007 Exhibit 2-7: 2001, Blood Substitution Incidence, by Condition Exhibit 2-8: 2002, Selected Plasma Volume Replacement Products, by Exhibit 2-9: 2002, Selected Plasma Volume Expanders Exhibit 2-10: Plasma Volume Replacement Products, Market Forecast, Exhibit 2-11: 2002, Indications for Heparin Therapy Exhibit 2-12: Indications for Warfarin Therapy Exhibit 2-13: 2002, Selected Factor VIII Products Exhibit 2-14: 2002, Selected Factor IX Products Exhibit 2-15: 2002, Selected Antiplatelet Agents Exhibit 2-16: 2002, Advantages of Plavix Exhibit 2-17: 2002, Populations at Risk for Developing Neutropenia Exhibit 2-18: 2002, Selected Immunoglobulin Intravenous Products Exhibit 2-19: Risk Factors for Peripheral Artery Disease Exhibit 2-20: Indications for Antifibrinolytic Therapy Exhibit 2-21: Indications for Desmopressin Therapy Exhibit 2-22: Indications for Thrombolytic Agent Therapy Exhibit 2-23: 2001, Blood Modifiers Market, Share by Supplier Exhibit 2-24: Blood Modifiers, Market Forecast, 2001-2007 Exhibit 2-25: Selected Surgical Applications for Blood Salvaging Exhibit 2-26: Blood Salvaging Products, Market Forecast, 2001-2007 Exhibit 3-1: Advantages and Disadvantages of Stem Cells, by Source Exhibit 3-2: 2002, Registered Stem Cell Institutions Exhibit 3-3: Malignant Disorders Treated Using Bone Marrow Transplantation Exhibit 3-4: Advantages and Disadvantages of Bone Marrow Transplantation, Exhibit 3-5: 2002, Techniques Used for Purging Stem Cells of Tumor Cells Exhibit 3-6: Bone Marrow Versus Peripheral Blood Stem Cell Transplantation Exhibit 3-7: Indications for Allogenic and Autologous Stem Cell Therapy Exhibit 3-8: Gene-Modified Stem Cell Therapy Applications for Genetic Exhibit 3-9: 2001, Number of Patients on the National Patient Waiting List for Exhibit 3-10: Stem Cell Transplantation, Procedure Volumes Forecast, by Type, Exhibit 3-11: Stem Cell Transplantation, Procedure Volumes Forecast, by Exhibit 3-12: 2002, Selected Stem Cell Extraction Devices Exhibit 3-13: Stem Cell Extractors and Disposables, Market Forecast, Exhibit 3-14: 2002, Aastrom Biosciences, Hematopoietic Stem Cell Product Exhibit 3-15: Advantages and Disadvantages of Using Umbilical Cord Blood as Exhibit 3-16: 2001, Private Umbilical Cord Blood Banking Market, Share by Exhibit 3-17: Umbilical Cord Blood, Unit Volumes Forecast, 2001-2007 Exhibit 3-18: Umbilical Cord Blood Products, Market Forecast, 2001-2007 *** This is a partial list of companies, for a full listing request it ***
* Single License allows for report sharing within one company location.
In 2001, the U.S. apheresis, hemostasis, and stem cell therapy products market totaled $580.2 million, a figure that is expected to more than double over the forecast period covered by this report. Technologies such as blood modification, salvaging, and substitution; stem cell expansion and transplantation; and therapeutic apheresis will drive market growth.
This report from Medtech Insight presents a detailed overview of apheresis, hemostasis, and stem cell therapy technologies and markets, along with 15 company profiles.
Major topics include: donor apheresis; therapeutic apheresis; blood disorders; metabolic disorders; blood substitutes; blood transfusions; plasma volume replacement; blood modifiers; blood salvaging; stem cell transplantations; stem cell expansion ex vivo; and umbilical cord blood collection.
i. Introduction
ii. Scope and Methodology
iii. The Apheresis Products Market
iv. The Hemostasis Products Market
v. The Stem Cell Therapy Products Market
vi. Total Market Forecast
1.1 Apheresis
1.1.1 Donor Apheresis
1.1.2 Therapeutic Apheresis
1.2 Apheresis Applications
1.2.1 Platelet Therapy
1.2.2 Plasmapheresis
1.2.3 Erythrocytapheresis
1.2.4 Leukoreduction
1.3 Safety
1.4 Costs
1.5 Disadvantages of Single-Donor Collections
1.6 Therapeutic Apheresis
1.6.1 Types
1.6.1.1 Cytapheresis
1.6.1.2 Erythrocytapheresis
1.6.1.3 Extracorporeal Photophoresis
1.6.1.3.1 Development
1.6.1.3.2 Technique
1.6.1.3.3 Current and Developing Indications
1.6.1.4 Leukapheresis
1.6.1.5 Plasmapheresis
1.6.1.6 Therapeutic Phlebotomy
1.6.1.7 Thrombocytapheresis
1.6.2 Indications and Protocols
1.6.2.1 Neurologic Conditions
1.6.2.1.1 Amyotrophic Lateral Sclerosis
1.6.2.1.2 Chronic Inflammatory Demyelinating
Polyneuropathy
1.6.2.1.3 Guillain-Barre Syndrome
1.6.2.1.4 Multiple Sclerosis
1.6.2.1.5 Myasthenia Gravis
1.6.2.2 Blood Disorders
1.6.2.2.1 Autoimmune Hemolytic Anemia
1.6.2.2.2 Cutaneous T-Cell Lymphoma
1.6.2.2.3 Hematologic Malignancy
1.6.2.2.4 Hemolytic Uremic Syndrome
1.6.2.2.5 Hemophilia
1.6.2.2.6 Idiopathic Thrombocytopenia Purpura
1.6.2.2.7 Neonatal Hemolytic Disease
1.6.2.2.8 Paraproteinemia
1.6.2.2.9 Sickle Cell Anemia
1.6.2.2.10 Thrombotic Thrombocytopenia Purpura
1.6.2.3 Renal Disease
1.6.2.3.1 Goodpasture's Syndrome
1.6.2.3.2 Immune-Complex Nephritis
1.6.2.3.3 Renal Transplantation
1.6.2.4 Rheumatic Disease
1.6.2.4.1 Systemic Lupus Erythematosus
1.6.2.4.2 Rheumatoid Arthritis
1.6.2.4.3 Inflammatory Myositis
1.6.2.5 Metabolic Disorders
1.6.2.5.1 Hyperlipidemia
1.6.2.5.2 Refsum's Disease
1.6.2.5.3 Age-Related Macular Degeneration
1.6.3 Reimbursement
1.7 Products
1.7.1 Current Equipment Technology
1.7.1.1 Centrifugation Systems
1.7.1.2 Membrane Filtration Systems
1.7.2 Technological Developments
1.7.2.1 Adsorption Devices
1.7.2.2 Elutriation Systems
1.7.2.3 Ultrafiltration
1.8 Trends in Apheresis Procedures
1.8.1 Donor Apheresis
1.8.2 Therapeutic Apheresis
1.9 Market Forecast
1.10 Market Analysis
2.1 Blood Supply
2.1.1 Paid Donors
2.1.2 Blood Safety
2.1.2.1 Products
2.2 Blood Components
2.2.1 Whole Blood
2.2.2 Red Blood Cells
2.2.3 Platelets
2.2.3.1 Supply
2.2.4 Plasma
2.2.5 Human Serum Albumin
2.2.6 Human Immunoglobulin
2.2.7 Cryoprecipitate/Coagulation Factors
2.3 Blood Collection
2.4 Blood Transfusions
2.4.1 Autotransfusion
2.4.2 Number of Transfusions
2.4.3 Surgery and Transfusions
2.4.4 Blood Screening
2.5 Blood Substitutes
2.5.1 Blood Substitute Technology
2.5.2 Products in Development
2.5.2.1 Alliance Pharmaceutical
2.5.2.2 Baxter International
2.5.2.3 Biopure
2.5.2.4 Enzon
2.5.2.5 Hemosol
2.5.2.6 Northfield Laboratories
2.5.2.7 Sonus Pharmaceuticals
2.5.2.8 Synthetic Blood International
2.5.3 Market Forecast
2.6 Plasma Volume Replacement Products
2.6.1 Colloid Solutions
2.6.1.1 Albumin
2.6.1.2 Dextran
2.6.1.3 Gelatin
2.6.1.4 Hydroxyethyl Starch
2.6.1.5 Plasma Protein Fraction
2.6.2 Crystalloid Solutions
2.6.2.1 Dextrose Solution
2.6.2.2 Hartmann's Solution
2.6.2.3 Normal Saline
2.6.3 Guidelines
2.6.4 Manufacturers
2.6.4.1 Abbott Laboratories
2.6.4.2 Instituto Grifols
2.6.4.3 ZLB BioPlasma/CSL
2.6.5 Recombinant Human Serum Albumin
2.6.6 Market Forecast
2.7 Blood Modifiers
2.7.1 Anticoagulants
2.7.1.1 Heparin
2.7.1.1.1 Indications
2.7.1.2 Warfarin
2.7.1.2.1 Indications
2.7.1.3 Anticoagulant Products
2.7.2 Hemophilia
2.7.2.1 Treatment
2.7.2.2 Factor VIII Inhibitors
2.7.2.3 Factor VIII
2.7.2.4 Recombinant Factor VIII
2.7.2.5 Factor IX
2.7.2.6 Factor VIIa
2.7.3 Antiplatelet Agents
2.7.3.1 Plavix
2.7.3.2 Persantine
2.7.3.3 Ticlid
2.7.3.4 ReoPro
2.7.3.5 Aggrastat
2.7.3.6 Integrilin
2.7.4 Colony Stimulating Factor
2.7.4.1 Neutropenia
2.7.4.2 Colony Stimulating Factor Agents
2.7.5 Hematinic Agents
2.7.5.1 Cyanocobalamin
2.7.5.2 Anabolic Steroids
2.7.5.3 Folates
2.7.5.4 Iron
2.7.5.5 Erythropoietin
2.7.5.6 Thrombopoietin Growth Factor
2.7.6 Immunoglobulins
2.7.6.1 Costs
2.7.6.2 Shortages
2.7.7 Hemorheologic Agents
2.7.7.1 Treatment
2.7.7.2 Treatment Agents
2.7.8 Hemostatics and Antifibrinolytic Agents
2.7.8.1 Antifibrinolytic Amino Acids
2.7.8.2 Desmopressin
2.7.8.3 Aprotinin
2.7.9 Thrombolytic Agents
2.7.9.1 Streptokinase
2.7.9.2 Urokinase
2.7.9.3 Tissue Plasminogen Activator
2.7.9.3.1 Disadvantages
2.7.10 Vitamin K
2.7.11 Market Analysis
2.7.12 Market Forecast
2.8 Blood Salvaging
2.8.1 Technology
2.8.2 Applications
2.8.3 Risks
2.8.4 Products
2.8.5 Market Forecast
3.1 Sources and Types of Stem Cells
3.2 Blood Cell Formation
3.2.1 Embryonic Stem Cells
3.2.1.1 Federal Funding
3.3 Stem Cell Transplantations
3.3.1 Bone Marrow Transplantations
3.3.1.1 Limitations
3.3.2 Peripheral Blood Stem Cell Transplantation
3.3.2.1 Advantages and Disadvantages
3.3.2.2 Collection, Storage, and Preparation
3.3.2.3 Mobilized Peripheral Blood
3.3.2.4 Infusion
3.3.3 Umbilical Cord Blood Transplantations
3.4 Stem Cell Selection and Cell Purging
3.4.1 Depletion Strategies
3.4.2 Positive Selection Techniques
3.4.3 Clinical Outcomes
3.5 Stem Cell Therapies
3.5.1 Cancer
3.5.1.1 Breast Cancer
3.5.2 Genetic Disorders
3.5.3 Heart Disease
3.5.4 Diabetes
3.5.5 Autoimmune Disorders
3.5.6 Immunodeficiencies
3.5.7 Diagnosis and Immunization
3.5.8 Organ Transplantation
3.5.8.1 Xenotransplantation
3.5.8.1.1 Limitations
3.6 Stem Cell Transplantation, Procedure Volumes
3.7 Minitransplantation
3.8 Technological Aspects
3.8.1 Companies and Products
3.8.1.1 Baxter International
3.8.1.2 CellPro
3.8.1.3 Gambro
3.8.1.4 Miltenyi Biotec/AmCell
3.8.1.5 Market Analysis
3.8.1.6 Market Forecast
3.8.2 Stem Cell Expansion Ex Vivo
3.8.2.1 Applications
3.8.2.2 Culture Conditions
3.8.2.3 Biotechnology
3.8.2.4 Serum-Free Culture
3.8.2.5 Bioreactors
3.8.2.5.1 Flat Bed Perfusion Systems
3.8.2.5.2 Hollow-Fiber Bioreactors
3.8.2.5.3 Suspension Culture Systems
3.8.2.6 Companies and Products
3.8.2.6.1 Aastrom Biosciences
3.8.2.6.2 Cytomatrix
3.8.2.6.3 Tissue Therapeutics/Montec Research
3.8.2.6.4 Viacell
3.8.2.7 Market Analysis
3.8.3 Umbilical Cord Blood
3.8.3.1 Collection and Storage
3.8.3.2 Private Versus Donor
3.8.3.3 Private Storage
3.8.3.3.1 Costs
3.8.3.4 Market Analysis
3.8.3.5 Market Forecast
4. COMPANY PROFILES
4.2 Abbott Laboratories, Inc.
4.3 Alliance Pharmaceutical Corporation
4.4 Amgen, Inc.
4.5 AstraZeneca Group
4.6 Aventis, Inc.
4.7 Baxter International, Inc.
4.8 Bayer AG
4.9 Biopure Corporation
4.10 Bristol-Myers Squibb Company
4.11 COBE Cardiovascular, Inc./SNIA Group
4.12 Fresenius HemoCare, Inc./Fresenius Medical Care AG
4.13 Haemonetics Corporation
4.14 Pharmacia Corporation
4.15 Wyeth, Inc.
COMPANY LISTING
2001-2007
Forecast, 2002 and 2007
Procedures
Kidney-Pancreas Transplants
Rates
2001-2007
by Supplier
Source
Indication
2001-2007
by Type
Disorders
Organ Transplantation
2001-2007
Disease, 2001-2007
2001-2007
Pipeline
a Source Material for Stem Cells
Supplier
Aastrom Biosciences, Inc.
Abbott Laboratories, Inc.
Alliance Pharmaceutical Corporation
Amgen, Inc.
AstraZeneca Group
Aventis, Inc.
Baxter International, Inc.
Bayer AG
Biopure Corporation
Bristol-Myers Squibb Company
COBE Cardiovascular, Inc./SNIA Group
Fresenius HemoCare, Inc./Fresenius Medical Care AG
Haemonetics Corporation
Pharmacia Corporation
+ MORE
** Corporate License allows for report sharing within all company locations.
This report is listed in the following markets:
Biomaterials, Biotechnology and Patient Management